Macrogenics (MGNX) Interest Coverage Ratio (2012 - 2026)
Macrogenics (MGNX) posted quarterly Interest Coverage Ratio of 6.11 for Q1 2026, up 98.69% year-over-year from 3.08 in Q1 2025, and down 115.92% quarter-over-quarter from 2.83 in Q4 2025.
Macrogenics (MGNX) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Interest Coverage Ratio for 15 consecutive years, with 6.11 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 98.69% year-over-year to 6.11; the TTM figure through Mar 2026 stood at 11.64 (up 99.15% YoY), while the FY2025 annual figure was 8.56, down 3007.03% from the prior year.
- Interest Coverage Ratio declined to 6.11 in Q1 2026 per MGNX's latest filing, from 2.83 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2201.54 in Q4 2024 and bottomed at 9696.83 in Q2 2024.
- Historically, Interest Coverage Ratio has averaged 737.65 across 5 years, with a median of 6.11 in 2026.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio slumped 45039.17% — and 2025, when it jumped 99.53%.
- Macrogenics' Interest Coverage Ratio stood at 73.71 in 2022, then soared by 70.86% to 21.48 in 2023, then soared by 10348.27% to 2201.54 in 2024, then tumbled by 100.13% to 2.83 in 2025, then slumped by 115.92% to 6.11 in 2026.
- Business Quant data shows MGNX's Interest Coverage Ratio at 6.11 in Q1 2026, 2.83 in Q4 2025, and 5.58 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -6.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.11 |
| Dec 31, 2025 | -2.83 |
| Sep 30, 2025 | 5.58 |
| Jun 30, 2025 | -45.83 |
| Mar 31, 2025 | -468.40 |
| Dec 31, 2024 | 2,201.54 |
| Jun 30, 2024 | -9,696.83 |
| Mar 31, 2024 | -1.16 |
| Jun 30, 2023 | -21.48 |
| Mar 31, 2023 | -4.91 |
| Mar 31, 2022 | -73.71 |
| Dec 31, 2021 | -0.18 |
| Sep 30, 2021 | -2.66 |
| Jun 30, 2021 | -0.75 |
| Mar 31, 2021 | -0.56 |
| Dec 31, 2020 | -0.01 |
| Sep 30, 2020 | -0.93 |
| Jun 30, 2020 | -0.87 |
| Mar 31, 2020 | -38.35 |
| Dec 31, 2019 | -24.16 |